Diastolic dysfunction can lead to heart failure with preserved ejection fraction, for which there is no effective therapeutic. Ranolazine has been reported to reduce diastolic dysfunction, but the specific mechanisms of action are unclear. The effect of ranolazine on diastolic function was examined in spontaneously hypertensive rats (SHRs), where left ventricular relaxation is impaired and stiffness increased. The objective of this study was to determine whether ranolazine improves diastolic function in SHRs and identify the mechanism(s) by which improvement is achieved. Specifically, to test the hypothesis that ranolazine, by inhibiting late sodium current, reduces Ca 2ϩ overload and promotes ventricular relaxation and reduction in diastolic stiffness, the effects of ranolazine or vehicle on heart function and the response to dobutamine challenge were evaluated in aged male SHRs and Wistar-Kyoto rats by echocardiography and pressure-volume loop analysis. The effects of ranolazine and the more specific sodium channel inhibitor tetrodotoxin were determined on the late sodium current, sarcomere length, and intracellular calcium in isolated cardiomyocytes. Ranolazine reduced the end-diastolic pressure-volume relationship slope and improved diastolic function during dobutamine challenge in the SHR. Ranolazine and tetrodotoxin also enhanced cardiomyocyte relaxation and reduced myoplasmic free Ca 2ϩ during diastole at high-stimulus rates in the SHR. The density of the late sodium current was elevated in SHRs. In conclusion, ranolazine was effective in reducing diastolic dysfunction in the SHR. Its mechanism of action, at least in part, is consistent with inhibition of the increased late sodium current in the SHR leading to reduced Ca 2ϩ overload. diastolic dysfunction; late sodium current; heart function; cardiomyocyte; ranolazine ABNORMAL LEFT VENTRICULAR (LV) diastolic function has been clearly associated with increased cardiovascular morbidity and mortality and is the underlying cause of heart failure with preserved ejection fraction (HFpEF). Two important risk factors for this condition are hypertension and advanced age. Diastolic dysfunction results from impaired LV relaxation and an increase in LV wall stiffness, both of which impede blood flow into the ventricle. As dysfunction worsens, there is a progressive increase in LV filling pressures to overcome structural and functional flow impediment. Dysfunction is exacerbated by exercise and high heart rates and can be measured by echocardiography and/or by LV pressure-volume (P-V) catheter. Current therapies for systolic heart failure have proven ineffective in HFpEF (6), and recent clinical trials for new approaches targeting diastolic dysfunction in HFpEF have also yielded disappointing results (27). Clearly, there is a significant need to better understand the pathology of diastolic dysfunction, to develop new study paradigms, and to identify and evaluate new therapeutic options for HFpEF (7).
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There is currently much interest in the potential use of the antianginal drug ranolazine in HFpEF patients (16, 30) . Although originally developed to inhibit partial fatty acid oxidation to reduce myocardial oxygen demand (5) , ranolazine has a number of pharmacological actions. It is a ␤-adrenergic receptor blocker (18) and an inhibitor of the hERG potassium channel but is best known as a selective inhibitor of the late sodium current (I Na,L ) (3). Hypertension, ischemia, and heart failure have been shown to increase the magnitude of I Na,L in cardiomyocytes from both animals and humans (20) . Enhanced I Na,L can elevate diastolic Na ϩ levels that in turn elevates diastolic Ca 2ϩ levels via the sodium-calcium exchanger, slowing relaxation (30, 33) . It is proposed that I Na,L could be an important therapeutic target to reverse Ca 2ϩ overload and thus improve LV relaxation in chronic diastolic dysfunction characteristic of HFpEF.
Several experimental studies have demonstrated that ranolazine, apparently by inhibiting I Na,L , reduced diastolic cytosolic Ca 2ϩ levels when acute diastolic dysfunction was induced by ischemia or ischemic agents (30) . However, in mice with diastolic dysfunction, ranolazine improved diastolic function by modulating myofilament Ca 2ϩ sensitivity and apparently not by inhibiting I Na,L (19) . To investigate the role of I Na,L in diastolic dysfunction, we tested the hypothesis that ranolazine improves diastolic function in the spontaneously hypertensive rat (SHR) by modulating I Na,L . Similar to the human condition, SHRs develop diastolic dysfunction associated with cardiac hypertrophy and chronic hypertension that progressively worsen with age. SHRs have been extensively used in the evaluation of therapeutic agents, but only recently has the effect of ranolazine been studied in this model (1, 25) . Because diastolic dysfunction is exacerbated at high heart rates and impairs the lusitropic response, we also determined the effect of ranolazine on the response to dobutamine infusion in vivo and frequency-dependent responses in isolated ventricular cardiomyocytes in vitro.
METHODS

Animals.
All animal protocols were in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the University of British Columbia Animal Care Committee. Studies were performed using male SHRs and Wistar-Kyoto (WKY) retired breeder rats (Harlan), aged 9 -11 mo, and were obtained and acclimatized for a minimum of 1 wk before the study. Diastolic function was evaluated by echocardiography in 7 SHRs and 6 WKY rats, and by P-V catheter in 14 SHRs and 14 WKY rats divided into ranolazine-and salinetreated groups. Since isoflurane potently inhibits I Na,L (15) , pentobarbital sodium anesthesia (50 -65 mg/kg) was used during all in vivo experiments. During P-V catheter studies, rats received preoperative buprenorphine analgesia (0.05 mg/kg sc) and supplemental pentobarbital sodium as required based on plantar reflex monitoring (every 10 min) of the depth of anesthesia. Rats were euthanized by pentobarbital sodium overdose (120 mg/kg) following P-V catheter studies or cervical dislocation under pentobarbital sodium anesthesia before isolation of cardiomyocytes.
Echocardiography. Image collection and analysis were performed by a technician blinded to rat strain or treatment. Rats were anesthetized (50 -60 mg/kg pentobarbital sodium ip) and placed supine on the warmed stage of a Vevo 2100 rodent echocardiography system (Visualsonics, Toronto, Canada). Parasternal long-and short-axis two-chamber M-mode views were obtained at midpapillary level and averaged to determine LV dimensions at end-systole and end-diastole. LV volumes, cardiac output, fractional shortening, and ejection fraction were calculated (Visualsonics software). Transmitral flow and septal mitral annulus velocity were assessed from a four-chamber apical view. Color Doppler was used to locate peak transmitral flow velocity. Parameters measured were early (E) and atrial (A) wave peak velocities, isovolumic relaxation time (IVRT), E-wave deceleration time, and diastolic filling interval (start of E to end of A), with the ratio of E to A calculated. Peak early (e=), atrial (a=), and systolic (s=) annular velocities were recorded, and e=-to-a= and E-to-e= ratios were calculated.
On separate study days, rats received either ranolazine (30 mg/kg ip) or saline (0.5 ml/kg ip) after baseline image collection. Imaging was repeated 10 min after treatment. Dobutamine was then infused via a 24-gauge tail vein cannula, starting at 40 g·kg Ϫ1 ·min Ϫ1 (PHD 2000 infusion pump, Harvard Apparatus), with infusion rate titrated to obtain a heart rate of 450 Ϯ 10 beats/min. Once heart rate stabilized, the infusion was maintained while the imaging protocol was repeated.
P-V loop analysis. Heart function was determined by insertion of an LV P-V catheter (SciSense) in SHRs and WKY rats anesthetized (65 mg/kg pentobarbital sodium ip, supplemented with 10 -20 mg/kg bolus doses as required) and given preoperative analgesia (0.05 mg/kg buprenorphine) before intubation by tracheotomy. Rats were ventilated (Harvard Apparatus) with 100% O2 using a Bain circuit. One femoral artery and vein were cannulated for arterial blood pressure and dobutamine infusion, respectively. A snare was positioned around the inferior vena cava via a lateral abdominal incision. The right carotid artery was isolated for insertion of a 1.8-Fr pressure volume catheter (SciSense, London, Ontario, Canada). Blood gases and electrolytes were monitored (i-STAT, Abbott Point of Care) with ventilation modified as required. Rats received 1 to 2 ml/kg saline ip to compensate for fluid loss during surgery.
Rats were allowed to stabilize for 10 min after instrumentation before baseline measures were performed. At each measurement point, 10 -20 steady-state loops were collected with the ventilator switched off before rapid occlusion of the inferior vena cava to reduce preload. Baseline values were averaged from two to three measurements collected over 20 -30 min. Ranolazine (30 mg/kg ip) or vehicle (saline, 0.5 ml/kg ip) was then administered. Measurements were repeated 10 min later. Intravenous infusion of dobutamine at a rate of 10 g·kg Ϫ1 ·min Ϫ1 was then started. Measurements were made and the infusion rate doubled every 5 min (to a maximum rate of 100 l·kg Ϫ1 ·min Ϫ1 ). Inferior vena cava occlusions during dobutamine were not consistently successful due to a higher incidence of premature ventricular contractions during the occlusions, consistent with Ca 2ϩ overload. We therefore analyzed only steady-state data in this section of the experiment.
Electrophysiology. The INa,L was recorded from freshly isolated cardiomyocytes as previously described (31) by using the standard whole cell patch-clamp technique. Cells were continuously superfused at room temperature with the external solutions as described below. Patch pipettes were pulled from thin-walled borosilicate glass (World Precision Instruments) on a horizontal micropipette puller (Sutter Instruments). Electrodes had resistances of 1.5-2.5 M⍀ when filled with control filling solution. Analog capacity compensation and ϳ80% series resistance compensation were generally used during whole cell measurements. Whole cell current recordings and analysis were made using an Axopatch 200B amplifier and pClamp9. Data were sampled at 10 -20 kHz and filtered at 5-10 kHz. A step/ramp protocol was used to examine I Na,L active during repolarization of an action potential: cells were held at a holding potential of Ϫ100 mV. Membrane potential was then stepped to Ϫ140 mV for 10 ms to allow Na ϩ channels to be fully available for activation. This was followed by a step to ϩ30 mV for 100 ms and a ramp back to Ϫ100 mV for 100 ms. The I Na,L was measured as the peak of the sag generated during the ramp.
Measurement of sacomere length and myoplasmic Ca 2ϩ concentration. A suspension of the isolated ventricular cardiomyocytes was transferred to a chamber (Cell MicroControls, Norfolk, VA) that was precoated each day with laminin (1 mg/ml) to help immobilize the cells and fixed to the heated stage of an Olympus IX70 inverted microscope with 400ϫ quartz optics. The cells were continuously superfused with Tyrode solution consisting of 1.5 mmol/l CaCl 2 in 95% O 2-5% CO2 at 0.5-1 ml/min. The experiments were conducted at temperatures averaging from 34 -36°C, and the temperature in any one experiment was maintained to within Ϯ1°C by means of a thermistor-controlled preheater in the superfusion line.
An IonOptix (Milton, MA) video system measured sarcomere length at 240 Hz, calibrated by a stage micrometer. Field stimulation at intensities twice threshold was used to induce contractions at 0.5 Hz. Only rod-shaped cells with diastolic sarcomere lengths Ն1.70 m and without spontaneous contractions were selected. The measured parameters of contraction were resting or diastolic length, peak shortening following stimulation, time to 50% peak shortening from stimulus, and time to 50% relaxation following peak of shortening.
This system was also used to measure relative changes in the myoplasmic concentration of Ca 2ϩ in the isolated cardiomyocytes by ratiometric fluorometry after loading the cells with 1 mol/l fura-2 AM (Invitrogen) for 10 -30 min before transferring to the chamber. The intensity of the epifluoresence at 510 nm following dual excitation (340/380 nm) was recorded and analyzed using the IonWizard software package. The ratio of the intensity from both wavelengths in any one myocyte is proportional to the myoplasmic free Ca 2ϩ concentration and is relatively independent of changes in fura-2 and instrumentation sensitivity. Absolute ratio values may vary from cell to cell because of slight differences in experimental conditions. However, the relative fluorescent ratio change within any one myocyte reflects the relative change in the magnitude of myoplasmic free Ca 2ϩ . For this reason differences due to treatment or frequency were determined from the relative change as opposed to absolute ratio values.
Experimental protocol for studies of INa,L inhibition and contractile function. Inward currents from isolated cardiomyocytes were continuously recorded in the absence and then in the presence of 10 mol/l nifedipine, an L-type Ca 2ϩ current inhibitor to isolate Na ϩ currents. INa,L was then recorded in the absence and then in the presence of 10 mol/l ranolazine or 3 mol/l tetrodotoxin (TTX; 2 to 3 min exposure) at a stimulation frequency of 1 Hz. Following treatment with ranolazine or TTX, cells were exposed to a Na ϩ free N-methyl-Dglucamine (NMG)-based solution to eliminate Na ϩ channel conductance and establish the baseline current during the ramp. Analysis involved current trace averaging and leak subtraction for each condition (predrug, drug, and NMG). NMG traces were then subtracted from the predrug-and drug-averaged traces to measure total INa,L and the amount of INa,L remaining after drug treatment. In some experiments, NMG was replaced by a high concentration of TTX (50 mol/l).
Once a cardiomyocyte was selected for study of sarcomere length, the 0.5-Hz base stimulation rate was continued for at least 2 min in Tyrode to establish a baseline response. A length-frequency protocol was then applied by progressively raising the stimulus frequency from 0.5 Hz to 1, 3, and then 6 Hz, each for a period of 2.5 min before returning to the 0.5-Hz base rate. Within 2 to 3 min, the superfusate was switched to a Tyrode solution containing 10 mol/l ranolazine or 3 mol/l TTX and superfused for at least 10 min before repeating the length-frequency protocol. A series of time control experiments were also conducted using the identical protocol, except that the switched superfusates did not contain any drug. Spontaneous contractions and contractile waves were typically seen for 1 or 2 min immediately following the length-frequency trial.
When loaded with fura-2, the cardiomyocytes were much more sensitive to repetitive stimulation above 0.5 Hz and the parameters of the length-frequency trial was changed to a single 30-s period of 6 Hz, which was just sufficient to reach steady state. Because of the potential for significant buffering of intracellular Ca 2ϩ , sarcomere length changes were not simultaneously measured.
Solutions and drugs. Tyrode solution consisted of (in mmol/l) 121 NaCl, 5 KCl, 2.8 Na-acetate, 1 MgCl 2, 24 NaHCO3, 1 Na2HPO4, 5.5 glucose, and CaCl2 at 1.5 unless otherwise noted. After equilibrating with 95% O2-5% CO2, the pH was 7.4.
External solution for INa,L recording consisted of (in mmol/l) 130 NaCl, 5 CsCl, 10 dextrose, 10 HEPES, 1 MgCl2, 1 CaCl2, and 0.01 nifedipine (pH was set to 7.4 with NaOH). The NMG-based solution contained (in mmol/l) 140 NMG, 10 HEPES, and 1 MgCl2. Internal solution contained (in mmol/l) 35 NaCl, 105 CsF, 10 EGTA, and 10 HEPES (pH was set to 7.2 with NaOH). Values are means Ϯ SE. Septal mitral annular peak velocity was measured at systole (s=) and for early (e=) and atrial (a=) diastolic waves and peak trans-mitral blood flow velocity of early (E) and atrial (A) waves are shown. WKY, Wistar-Kyoto; SHR, spontaneously hypertensive rat; LV, left ventricle; P-V, pressure-volume; IVRTc, isovolumetric relaxation time corrected; Ees, end-systolic elastance, calculated as the slope of the relationship Pes ϭ a·V es 2 ϩ b·Ves ϩ c, where Pes is end-systolic pressure, and Ves is end-systolic volume. ϮdP/dtmax, maximun rate of increase or decrease in LV pressure. End-diastolic P-V relationship (EDPVR) slope or the stiffness coefficient (␤) was calculated by an exponential curve fit (P ϭ Ce ␤V ); time constant () was calculated using the Glantz method. Echocardiography interval data were corrected for heart rate using Bazett's formula. Data were compared by unpaired t-test. P values shown in boldface indicate statistical significance. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001. 
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Ranolazine (Sigma-Aldrich) and TTX (Alomone) were resuspended in water to obtain stock solutions of 50 and 3 mmol/l, respectively, for in vitro experiments. Nifedipine (Sigma-Aldrich) was prepared as a 10 mmol/l stock solution in DMSO. For in vivo experiments, ranolazine and dobutamine (Sigma-Aldrich) were freshly dissolved in saline on the day of experiment.
Analysis. To account for heart rate, interval data (IVRT, E-wave deceleration time, diastolic filling interval) were corrected using Bazett's formula. SHRs and WKY rats were compared by unpaired t-test. In echocardiography experiments, effects of ranolazine or saline before and during dobutamine were compared by two-way ANOVA with repeated measures (both factors) with Bonferroni post hoc (GraphPad Prism 6) to account for repeated measures in each rat. In P-V loop experiments, raw data or the relative change from baseline after treatment or during dobutamine was determined for each rat and compared by two-way ANOVA with Bonferroni post hoc. For the in vitro experiments, unpaired t-test or a one-way or two-way ANOVA was used to determine mean differences between SHRs and WKY rats and between treatment groups at a given frequency. Significance was defined as P Ͻ 0.05. Data are presented as means Ϯ SE.
RESULTS
Diastolic function in SHRs and WKY rats.
Baseline values for echocardiographic and hemodynamic parameters are summarized in Table 1 . Heart rate was faster in SHRs during both echocardiography and P-V loop experiments. Posterior LV wall thickness was increased in SHRs with similar chamber volumes, suggesting LV hypertrophy. Ejection fraction was similar, whereas fractional shortening, cardiac output, and systolic mitral annular velocity (s=) were higher in SHRs, consistent with enhanced systolic function as previously reported (9) . When diastolic functions were compared, the tissue Doppler e=-to-a= ratio was lower in SHRs, but there was no difference in transmitral E-or A-wave blood flow velocities, E-to-A ratio, or the E-to-e= ratio. However, IVRT was longer in SHRs, whereas diastolic filling time was shorter than WKY rats. Representative pulsed-wave Doppler images from WKY and SHRs are shown in Fig. 1 , A and B. Collectively, these data suggest enhanced systolic function, delayed LV relaxation, and an increased atrial contribution to diastolic filling during an abbreviated filling interval in SHRs relative to WKY rats.
Data from P-V loop experiments largely corroborated these observations (Table 1) . Representative P-V loops collected during vena cava occlusion are shown in Fig. 2 . As expected for SHRs, mean arterial and LV end-systolic pressures and arterial elastance were higher than in WKY rats. Increased contractility was indicated by a significantly higher end-systolic elastance in SHRs than WKY rats. Comparison of diastolic function demonstrated that the slope of the end-diastolic P-V relationship (EDPVR) was steeper in SHRs than WKY rats, and end-diastolic pressure was also slightly, but significantly, higher. The time constant () of LV relaxation was longer in SHRs.
Effect of ranolazine on diastolic function in SHRs and WKY rats. By echocardiography, the effects of ranolazine (30 mg/ kg) or vehicle (0.5 ml/kg saline) in each rat were directly compared by paired observations made on separate study days by a sonographer blinded to rat strain and treatment. Ranolazine had little effect on baseline echocardiographic parameters (Table 2) . It decreased heart rate in both strains, but this reached significance only in SHRs, where cardiac output also decreased. Relative to saline treatment, there was a decrease in a= velocity in WKY rats after ranolazine treatment, and higher A-wave velocity in SHRs, but no change in the timing of relaxation or early filling parameters. Representative pulsedwave Doppler images from saline and ranolazine-treated SHRs are shown in Fig. 1 , C and D.
Since P-V catheter experiments were terminal, the effects of ranolazine or vehicle were determined in separate groups of rats to ensure that time and volume loading effects did not confound comparisons. The relative change from baseline after treatment was therefore compared among groups. Representative P-V loops obtained during vena cava occlusion in WKY and SHRs are shown in Fig. 2 , A and B, at baseline and after either saline or ranolazine treatment. Ranolazine reduced heart rate, mean arterial pressure, maximum rate of increase or decrease in LV pressure (ϮdP/dt max ), and stroke work (Table 3) in both SHRs and WKY rats. LV contractility (⌬end-systolic elastance) was not significantly changed, however, suggesting that although ranolazine lowered heart rate and arterial pressures in both strains, it was not a negative inotrope at this dose.
There was a specific effect of ranolazine on diastolic function in SHRs, where the EDPVR slope was reduced (Fig. 2C) . However, end-diastolic pressure was not significantly decreased (Fig. 2D) , and LV increased in the presence of ranolazine (Table 3) . Ranolazine altered heart rate and loading conditions markedly, as has been previously reported in anesthetized animals (13) . Because the rate of LV relaxation and early diastolic filling is intrinsically linked to heart rate and loading conditions (8) , beneficial effects of ranolazine on cardiomyocyte and thus LV wall relaxation evaluated by IVRT or may have been countered by slowing of relaxation associated with decreasing heart rate and load. The main measurable effect of ranolazine on diastolic function was to decrease the load-independent measure of end-diastolic stiffness, ED-PVR slope.
Effect of ranolazine on the response to dobutamine. To better understand how ranolazine influenced LV relaxation in vivo, we administered the adrenergic agonist dobutamine. Because of balanced ␣ 1 -and ␤-adrenergic receptor agonist actions, dobutamine exerts both positive inotropic and lusitropic changes with minimal changes in peripheral resistance. We hypothesized that SHRs with diastolic dysfunction would exhibit impaired lusitropic responses to dobutamine relative to WKY rats and that ranolazine would improve the lusitropic response in SHRs.
During echocardiography, heart rate was increased to 450 Ϯ 10 beats/min by titrated dobutamine infusion, and effects of prior ranolazine or saline treatment were compared by paired analysis. Representative pulsed-wave Doppler images col- lected during dobutamine infusion are shown in Fig. 1, E and F. The inotropic responses to dobutamine in SHRs and WKY rats were similar in terms of the increase in cardiac output, ejection fraction, and fractional shortening ( Table 2) . Dobutamine also had lusitropic effects on diastolic function. Both E and e= increased during dobutamine infusion in both groups (Fig. 3, A and B) . Ranolazine treatment further enhanced the lusitropic effect of dobutamine on e= in WKY and on E in SHRs. IVRT heart rate corrected (IVRT c ) increased during dobutamine infusion in both WKY and SHRs after saline, but ranolazine treatment prevented this nonlusitropic effect (Fig. 3,  C and D) .
In P-V loop experiments, the effects of sequentially infusing 10, 20, and 40 g·kg Ϫ1 ·min Ϫ1 dobutamine were determined after 5 min at each infusion rate in SHRs and WKY rats treated either with saline or ranolazine. Pertinent values are reported in Table 4 . Ranolazine inhibits ␤ 1 -and ␤ 2 -adrenoceptors (18) , and consequently the dose-dependent increase in heart rate and ϩdP/dt during dobutamine infusion in both WKY and SHRs were right-shifted by ranolazine. Consistent with its inotropic effect, however, dobutamine dose-dependently increased heart rate, ejection fraction, cardiac output, end-diastolic pressure, and ϮdP/dt max . Stroke volume was maintained at all dobutamine infusion rates. Mean arterial pressure decreased in saline-treated SHRs and WKY rats, was unchanged in ranolazine-treated SHRs, and increased in ranolazine-treated WKY rats ( Table 4 ). The absolute heart rate was lower in ranolazine than saline-treated rats at all doses.
Dobutamine also dose-dependently increased end-diastolic pressures. At 40 g·kg Ϫ1 ·min Ϫ1 , end-diastolic pressures were higher in saline SHRs than all other groups, suggesting exacerbation of increased LV stiffness. Ranolazine significantly reversed this effect of dobutamine (Table 4) . While this effect may be in part due to ␤-blockade lowering heart rate, enddiastolic pressures in SHRs in the presence of ranolazine and dobutamine (0.29 -1.1 mmHg at 340 -424 beats/min) were considerably lower than baseline (2.4 mmHg at 308 beats/min) despite baseline heart rate being slower. tended to increase in dobutamine (P ϭ 0.078) and to a lesser extent in the presence of ranolazine but differences did not reach significance (Table  4 ). These data suggest that at the target heart rate achieved during echocardiography-dobutamine studies, end-diastolic pressure increases were likely minimal. Thus the shorter IVRT c interval in the ranolazine-treated SHR group is unlikely to result from increased filling pressures, rather it is likely to be from a more direct effect of ranolazine on myocardial relaxation.
Effect of ranolazine and TTX on I Na,L in isolated ventricular cardiomyocytes. Ranolazine is known to inhibit I Na,L . Thus, to investigate the potential mechanism of action whereby ranolazine improved diastolic function in SHRs, we determined the current density of I Na,L in SHR and WKY cardiomyocytes and the extent to which it was inhibited by a clinically relevant concentration of ranolazine. The voltage-clamp protocol that simulates a cardiac action potential and the currents following procedures to isolate specific ion conductances are shown in Fig. 4 . Since ranolazine is not a specific inhibitor of I Na,L , its effects were compared with a level of TTX known to be specific for sodium channels and somewhat selective for I Na,L (11) . I Na,L normalized to cell capacitance (current density) was significantly larger in SHR than WKY cardiomyocytes (Fig.  4C) . Ranolazine (10 mol/l) inhibited I Na,L but was significantly less potent in SHR (17 Ϯ 3% inhibition) than WKY (33 Ϯ 7% inhibition) cardiomyocytes (Fig. 4, A and D) . TTX (3 mol/l) was significantly more potent at inhibiting I Na,L and had similar potency in SHR and WKY cardiomyocytes (Fig. 4,  B and E) . These results suggest the presence of Na ϩ channel remodeling in the SHR, which specifically modulates the activity of ranolazine on I Na,L .
Sarcomere length and Ca 2ϩ transients in isolated cardiomyocytes from WKY and SHRs. The sarcomere length of single isolated cardiomyocytes was measured to capture the magnitude of diastolic and systolic lengths as well as the kinetics of transient shortening. Cardiomyocytes were stimulated at 0.5 Hz for the duration of the experiment, except during the application of the length-frequency response stimulus protocol of 1, 3, and 6 Hz, each for 150 s before returning to the 0.5-Hz baseline rate (Fig. 5A) . This resulted in a frequency-dependent decrease in systolic sarcomere shortening (fractional shortening), consistent with a negative force or length-frequency response, and a decrease in the extent of relaxation (diastolic length) between contractions (Fig. 5, B and C) . Consistent with frequency-dependent acceleration of relaxation, the half time Values are means Ϯ SE. Rats received either saline (0.5 ml/kg) or ranolazine (30 mg/kg) on separate study days. Measurements were taken before infusion of dobutamine was initiated to raise heart rate to 450 Ϯ 10 beats/min. Interval data were corrected for heart rate using Bazett's formula. N/A, not applicable. Data were compared by 2-way ANOVA with repeated measures (mixed model). #P Ͻ 0.05 and ##P Ͻ 0.01, ranolazine group vs. saline group. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001 vs. baseline values within group. of relaxation was decreased at higher frequencies in both strains (Fig. 5D) .
Only myocytes with a minimum diastolic sarcomere length of 1.7 m at 0.5 Hz were studied (n ϭ 94), since this was presumed to represent the lower limit for healthy cells. Only five myocytes had diastolic lengths Ͼ1.90 m. Despite this selected population, SHR cardiomyocytes on average had significantly shorter diastolic lengths than that of WKY rats at all stimulus frequencies (Fig. 5B) . There was no difference between the two strains in the amount of fractional shortening, rate of relaxation (Fig. 5, C and D) , or rate of contraction (not shown). These data indicate that SHR cardiomyocytes do not relax to the same extent as WKY rats.
A separate series of studies was conducted with isolated cardiomyocytes to measure cytosolic diastolic free Ca 2ϩ concentration and Ca 2ϩ transients using the fura-2 fluorescence technique (Fig.  6) . The diastolic Ca 2ϩ increased and the transient amplitude decreased when the stimulation rate was increased from 0.5 to 6 Hz (Fig. 6, B and C) . This is consistent with the reduction in diastolic sarcomere length observed at these stimulus frequencies (Fig. 5B) . Similarly, the Ca 2ϩ transient amplitude and the kinetics of the Ca 2ϩ transients were consistent with the kinetics for sarcomere shortening, with the single exception of a slightly, but significantly, longer half-time for decay of the Ca 2ϩ transient in SHRs at 0.5 Hz (Fig. 6, C and D) .
Immediately after the length-frequency response train, peak systolic shortening at 0.5 Hz was initially potentiated about 5% relative to the beginning of the train sequence. Over the next 3 to 4 min, this potentiated response decreased and tended to levels slightly less than before the train. Similarly, the diastolic length increased over the 3 to 4 min following the train sequence, but the Values are means Ϯ SE. In P-V loop experiments, we determined the effect of 5 min infusion of 10, 20, and 40 g·kg Cesium was used to block outward currents, and the remaining currents were processed by subtraction from the current recorded at the end of the experiment where N-methyl-D-glucamine was substituted for the sodium. The step-ramp voltage protocol simulates an action potential. Inward currents recorded during the 100-ms ramp back to Ϫ100 mV were sensitive to nifedipine, ranolazine,and tetrodotoxin (TTX). INa,L is presumed to be the current that remains after blockade of the Ca 2ϩ current with nifedipine. C: peak current density of INa,L normalized to cell total capacitance from 9 WKY and 7 SHR cells. D: inhibition of INa,L by ranolazine (10 mol/l). E: TTX (3 mol/l) in WKY and SHRs. *P Ͻ 0.05, unpaired t-test.
cardiomyocytes did not relax to the same extent as before the train (see time control traces in Figs. 7 and 8 ). Thus the myocytes did not fully recover from the length-frequency protocol, requiring time control comparisons for drug treatments.
The effect of ranolazine and TTX on sarcomere dynamics in isolated cardiomyocytes. In WKY cardiomyocytes, the only effect of ranolazine (10 mol/l) was to reduce fractional shortening relative to cardiomyocytes treated to the same stimulation protocol (time control) in the absence of drug exposure (Fig. 7B) . In SHRs, however, ranolazine increased the extent of diastolic relaxation between stimuli at higher frequencies (Fig. 7D ) and decreased the half-time for relaxation at lower frequencies (Fig. 7F) . Time to 50 and 90% of Ca 2ϩ transient baseline was unchanged in the presence of ranolazine (data not shown).
TTX (3 mol/l) had effects on SHR cardiomyocytes that were similar to ranolazine (Fig. 8) . Its only effect on WKY rats was to reduce fractional shortening (Fig. 8B) . Like ranolazine, in SHR, TTX enhanced the extent of diastolic relaxation at higher stimulation frequencies and the rate of relaxation at lower frequencies (Fig. 8, D and F) . Thus specific inhibition of Na ϩ conductance enhanced parameters of relaxation only in SHR cardiomyocytes.
The effect of ranolazine and TTX on Ca 2ϩ levels in isolated cardiomyocytes. Increasing the stimulus rate from 0.5 to 6 Hz increased cytosolic Ca 2ϩ levels during diastole in both WKY and SHR cardiomyocytes (Fig. 6B) . Ranolazine and TTX significantly reduced the accumulation in Ca 2ϩ at 6 Hz only in SHRs, consistent with their enhancement of sarcomere diastolic length (Figs. 7D, 8D , and 9). These agents had no significant effect on diastolic Ca 2ϩ levels in WKY rats, consistent with the idea that the elevated I Na,L contributes to impaired relaxation in SHRs.
DISCUSSION
In this study we have demonstrated diastolic dysfunction in SHRs relative to WKY rats which is exacerbated during dobutamine infusion and that ranolazine can improve certain parameters of diastolic dysfunction both at baseline and during dobutamine or frequency stress. In isolated cardiomyocytes, I Na,L was increased in SHRs and inhibited by ranolazine or TTX. Furthermore, ranolazine or TTX specifically reduced accumulation of diastolic Ca 2ϩ and increased sarcomere length in SHRs, especially at higher stimulation rates. Although ranolazine is not a specific I Na,L inhibitor, these data are consistent with the hypothesis that ranolazine can improve diastolic dysfunction in SHRs via modulation of I Na,L , leading to decreased Ca 2ϩ accumulation and improved cardiomyocyte relaxation.
Diastolic dysfunction in SHRs. Diastolic dysfunction, but not frank HFpEF, has been extensively described in 9 -14 mo SHRs. Both previous reports (9, 10, 28) and our data suggest a mild dysfunction phenotype characterized by impaired relax- ation, increased LV stiffness, and slightly elevated diastolic pressures. In this study, we also determined the response to dobutamine in SHRs and WKY rats. Heart rate is a major determinant of the rate of LV relaxation (8) . As heart rate increases, rapid LV relaxation in healthy hearts augments the atrial-ventricular pressure gradient. Loss of this response impacts the capacity to enhance early filling as the diastolic interval shortens during exercise or adrenergic challenge. In patients with diastolic dysfunction, augmentation of the atrialapical LV pressure gradient during dobutamine infusion was reduced, with greatest impairment in patients with mild dysfunction (23) . The prolongation of IVRT c during dobutamine suggests that SHRs recapitulate this aspect of clinical diastolic dysfunction. In P-V loop experiments, it was also apparent that at heart rates higher than those tested in echocardiography experiments, (490 -516 vs. 450 beats/min) end-diastolic pressures also increased in SHRs. Our data therefore imply a progressive impairment of LV relaxation, eventually associated with increased diastolic pressures in response to dobutamine in SHRs. At the cellular level, isolated SHR and WKY myocytes had similar contractile kinetics, though the extent of diastolic relaxation was less in SHRs at each frequency tested. Furthermore, stimulation at 6 Hz, a physiological frequency for the rat, increased the myoplasmic Ca 2ϩ load in SHRs significantly more than in WKY rats. Even at 0.5 Hz, the decay rate of the Ca 2ϩ transient was significantly slower in SHRs than in WKY rats.
These data suggest that cardiomyocytes isolated from 9 -11 mo SHRs have impaired relaxation and preserved contractility. Accumulation of intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) at highstimulation rates may contribute to this effect. The worsening of LV relaxation during dobutamine is consistent with development of cardiomyocyte Ca 2ϩ overload. Incomplete relaxation at the cardiomyocyte level could explain, at least in part, the increase in EDPVR slope observed in vivo. LV hypertrophy, fibrosis, and elevated afterload are present in SHRs and are likely to also contribute to diastolic dysfunction in vivo (10) .
Effect of ranolazine in SHRs. We hypothesized that sodiumdependent Ca 2ϩ accumulation contributed to diastolic dysfunction in SHRs. This is based on data from experimental models of heart failure where intracellular Na ϩ concentration ([Na ϩ ] i ) is elevated (12) as well as a report of increased intracellular Na ϩ in SHR relative to WKY cardiomyocytes (17) . Action potential duration is prolonged in SHRs (34) . We (23) and others (1) have observed that I Na,L is enhanced in SHRs and thus could contribute to prolonged action potential duration and Na ϩ loading in cardiomyocytes. Thus we would predict that inhibition of I Na,L would improve diastolic function in SHRs.
We have demonstrated that ranolazine decreased end-diastolic LV stiffness in SHRs, similar to effects reported in mice with diastolic dysfunction secondary to DOCA-salt administration (19) . Recently, acute ranolazine treatment also reduced LV end-diastolic pressure in a small cohort of HFpEF patients, although indexes of relaxation were unaltered (21) . More importantly, a recent study in SHRs demonstrated that chronic treatment with ranolazine over 3 months resulted in improvement of Ca 2ϩ cycling kinetics relative to untreated SHRs (1).Though there was no change in echocardiographic mea- sures of cardiac function, there was a significant decrease in the development of T-tubule disorganization with chronic ranolazine therapy, suggesting that chronic inhibition of I Na,L may be of therapeutic benefit for delaying progression of the disease.
These studies support a beneficial effect of ranolazine in diastolic dysfunction, but it is difficult to establish whether improvements in LV relaxation-demonstrated in several in vitro studies using ranolazine (30)-underlies this effect in vivo. Ranolazine also decreased heart rate and mean arterial pressure in our study, as previously observed in anesthetized rats (13) . Parameters of LV relaxation are, to varying extents, dependent on hemodynamic conditions. For instance, although e= has been correlated with and reflects the rate of LV relaxation (29) , it is also dependent on loading conditions and restoring forces generated by compression of elastic wall components during systole (24) . Given the enhanced systolic function in SHRs, this interaction may also explain the lack of difference in e= between SHRs and WKY rats at baseline. Similarly, since LV relaxation rate is intrinsically dependent on heart rate, is heart rate-dependent and is also influenced by loading changes (8, 26) . While we have corrected IVRT for heart rate, it is also influenced by lengthening load (22) . It is therefore possible that changes in relaxation at the cardiomyocyte level were offset by the opposing effects of slowed heart rate and decreased afterload. It should also be considered that, although the number of animals in each treatment group was intended to provide sufficient statistical power to detect significant changes in primary variables of interest, our sample size may not have been adequate to detect more subtle treatment effects across all of the variables measured.
To better understand the effect of ranolazine on LV relaxation, we also determined the response to dobutamine. Dobutamine exerts positive inotropic and lusitropic effects via myocardial ␤ 1 -and ␣ 1 -adrenergic receptor activation to enhance sarco(endo)plas- mic reticulum Ca 2ϩ -ATPase 2A function and has been previously used in rats during echocardiographic evaluation of systolic (32) and diastolic function (2) . To overcome heart rate differences due to strain and ␤-blockade by ranolazine, dobutamine infusion rate was varied to achieve a heart rate of 450 Ϯ 10 beats/min in all groups. Ranolazine protected against further IVRT prolongation during dobutamine and thus enhanced relaxation. The dose-response to dobutamine was determined in P-V catheter experiments. Data were consistent with the interpretation that enhanced LV relaxation, as opposed to elevated filling pressures, prevented IVRT from increasing during dobutamine in ranolazine-treated SHRs. Indeed, elevated end-diastolic pressure occurred only in saline-SHRs at very high heart rates. Collectively, our data suggest that ranolazine improved the lusitropic response to dobutamine.
Effects of ranolazine on cardiomyocytes. Our in vitro observations are consistent with the hypothesis that I Na,L is increased in SHRs, which in turn increases diastolic Ca 2ϩ accumulation, contributing to Ca 2ϩ overload especially at higher stimulation rates, and that ranolazine enhances relaxation and improves diastolic function by inhibiting this increased I Na,L , thus reducing diastolic Ca 2ϩ : 1) We determined that I Na,L is indeed elevated in SHRs relative to WKY rat age-matched controls.
2) We demonstrated that following stimulation diastolic Ca 2ϩ levels were elevated in SHRs relative to WKY rats and that the sarcomere diastolic length was shorter.
3) We established that ranolazine was an inhibitor of I Na,L in SHR and WKY rat cardiomyocytes.
4)
We did observe that ranolazine enhanced relaxation as evidenced by increased diastolic sarcomere lengths. This effect was only seen in SHRs and not WKY rats and was not seen at 0.5 Hz but only at higher stimulus rates which could contribute to Ca 2ϩ overload. 
5)
Ranolazine treatment lowered diastolic Ca 2ϩ accumulation and, like its effect on diastolic sarcomere length, did so only in SHR cardiomyocytes.
Inhibition of I Na,L and subsequent decrease in [Na ϩ ] i and [Ca 2ϩ ] i have been observed in a number of previous studies and is thought to be the principal mechanism by which ranolazine improves diastolic function in several animal models. However, a recent study where diastolic dysfunction was generated in mice by deoxycorticosterone acetate (DOCA)/salt loading concluded that ranolazine improves diastolic function by a different mechanism (19) . This study showed no increase in cardiomyocyte I Na,L and no effects of ranolazine on I Na,L but observed that ranolazine can act directly on myofilaments through a Ca 2ϩ desensitization mechanism. In contrast, our study demonstrates that SHRs develop diastolic dysfunction that is associated with elevated I Na,L as has been reported in diastolic dysfunction due to ischemia or heart failure in other mouse, rat, rabbit, and dog experimental models and in tissue samples from failing human hearts (20) . Furthermore, the effects of ranolazine were mimicked by TTX, which strongly suggests that the action of ranolazine was on Na ϩ channel function for which TTX is specific. Ranolazine was initially described as a partial fatty acid oxidation inhibitor. However, fatty acid oxidation inhibition by ranolazine requires high concentrations (12% inhibition at 100 M), whereas in our study as well as in others, cardiac function is improved in the presence of Յ20 M ranolazine (4). Furthermore, isolated myocytes used in the present study were superfused in the absence of fatty acids in the external solution. Thus it is unlikely that the effects of ranolazine observed here can be attributed to partial fatty acid oxidation inhibition.
We observed that ranolazine was less potent on I Na,L in the SHRs than in WKY rats. This is a novel observation and may suggest Na ϩ channel remodeling in SHR myocytes resulting in decreased sensitivity to I Na,L block by ranolazine. Others have shown that neuronal Na ϩ channel isoforms are upregulated in a pressure-overload rat model (35) , supporting the idea that changes in Nav isoform in SHR cardiac myocytes could contribute to an increase in I Na,L . The nature and extent of Nav channel remodeling in the SHR remains to be determined.
Despite decreased potency for I Na,L , ranolazine improved relaxation parameters only in SHR cardiomyocytes. Recording of the total inward currents during the ramp protocol also revealed a prominent late Ca 2ϩ current. Although not tested in this study, the inhibition of late Ca 2ϩ current by ranolazine (3) could also reduce Ca 2ϩ accumulation and improve diastolic function. While TTX had similar effects to ranolazine, we cannot confirm that ranolazine acts only on I Na,L .
Clinical significance. There is a substantial need for effective therapeutics to treat diastolic dysfunction in HFpEF patients. The present study indicates that ranolazine acutely improves diastolic function in an animal model where, similar to clinical diastolic dysfunction, there is a worsening of LV relaxation and eventual increase in end-diastolic pressures during ␤-adrenergic stress. In the recent Ranolazine for the Treatment of Diastolic Heart Failure Proof-of-Concept Trial, acute ranolazine treatment decreased end-diastolic pressure but had no effects on relaxation parameters in HFpEF patients (21) . In this small patient cohort, there were also no differences in noninvasive measures of diastolic function after 14 days treatment. To determine whether the subtle changes in diastolic function observed in our, and other, experimental studies translate into substantial clinical benefit in HFpEF patients may require a larger sample size.
A recent publication indicates that chronic inhibition of I Na,L using ranolazine slows both hypertrophy and development of ultrastructural and physiological defects associated with the progression of heart failure (1). Another study showed that LV relaxation dysfunction and elevated [Ca 2ϩ ] i were observed before development of hypertension and hypertrophy in SHRs (14) . These data suggest that rather than being a consequence of hypertrophy, enhanced I Na,L may contribute to Ca 2ϩ overload, causing the hypertrophic response observed in the SHR. Chronic treatment of hypertensive patients with a selective I Na,L inhibitor would determine whether or not these experimental observations can apply to humans. Such data are not available at this point. More selective I Na,L inhibitors are also needed to investigate the true therapeutic potential of targeting I Na,L in diastolic dysfunction.
ACKNOWLEDGMENTS
We thank Lubos Bohunek for performing echocardiography measurements and Dan Werry for conducting certain electrophysiology experiments.
GRANTS
This study was funded in part by the Heart and Stroke Foundation of British Columbia and Yukon. Fig. 9 . Effect of ranolazine (10 mol/l) and TTX (3 mol/l) on changes in diastolic Ca 2ϩ levels in isolated ventricular cardiomyocytes. The relative amount of increase in diastolic Ca 2ϩ during the 6-Hz train in the presence of drug relative to the increase in the absence of drug (control) is shown. For TC experiments, both the first and second train was in the absence of drug. A: WKY rats (n ϭ 9, 11, and 8 for TC, ranolazine, and TTX, respectively). B: SHRs (n ϭ 14, 11, and 11 for TC, ranolazine, and TTX, respectively). *P Ͻ 0.05 vs. TC, 1-way ANOVA.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s). 
AUTHOR CONTRIBUTIONS
